Tumor immune surveillance and ovarian cancer

Kandalaft, Lana; Motz, Gregory; Duraiswamy, Jaikumar; Coukos, George
March 2011
Cancer & Metastasis Reviews;Mar2011, Vol. 30 Issue 1, p141
Academic Journal
In the past few years, cancer immunotherapies have produced promising results. Although traditionally considered unresponsive to immune therapy, increasing evidence indicates that ovarian cancers are, in fact, immunogenic tumors. This evidence comes from diverse epidemiologic and clinical data comprising evidence of spontaneous antitumor immune response and its association with longer survival in a proportion of ovarian cancer patients; evidence of tumor immune evasion mechanisms and their association with short survival in some ovarian cancer patients; and finally pilot data supporting the efficacy of immune therapy. Below we will discuss lessons learned on the biology underlying ovarian cancer immune rejection or tolerance and we will discuss its association with clinical outcome. We will discuss the role of angiogenesis and the tumor endothelium on regulation of the antitumor immune response with a special emphasis on the role of vascular endothelial growth factor (VEGF) in the suppression of immunological processes, which control tumor progression and its unique crosstalk with endothelin systems, and how their interactions may shape the antitumor immune response. In addition, we will discuss mechanisms of tumor tolerance through the suppression or exhaustion of effector cells and how these could be countered in the clinic. We believe that understanding these pathways in the tumor microenvironment will lead to novel strategies for enhancing ovarian cancer immunotherapy.


Related Articles

  • Antiangiogenic Therapy and Ovarian Cancer. Penson, Richard T.; Rauh-Hain, J. Alejandro; Horowitz, Neil S. // Current Women's Health Reviews;2008, Vol. 4 Issue 1, p33 

    Epithelial ovarian cancer is the most lethal of gynecologic malignancies in the United States and while current therapies are successful for many years, cure remains elusive. Angiogenesis is the physiological process of new blood vessel growth, and a normal process in growth, development, and...

  • Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts. Wei Li; Liang Wan; Ling-Yun Zhai; Jane Wang // International Journal of Molecular Sciences;Oct2014, Vol. 15 Issue 10, p19265 

    This study was designed to evaluate the effect of cyclooxygenase-1 (COX-1) inhibitor, SC-560, combined with cisplatin or taxol, on angiogenesis in human ovarian cancer xenografts. Mice were treated with intraperitoneal (i.p.) injections of SC-560 6 mg/kg/day, i.p. injections of cisplatin 3 mg/kg...

  • Current Management of Advanced and Metastatic Renal Cell Carcinoma. Ather, M. Hammad; Masood, Nehal; Siddiqui, Tahmeena // Urology Journal;Jan2010, Vol. 7 Issue 1, p1 

    Introduction: Unresectable renal cell carcinoma (RCC) is a technically incurable condition. Historically, RCC is resistant to chemotherapy and radiotherapy. Cytokine therapy was until recently considered the mainstay of treatment. However, responses are modest. Improvement in the understanding...

  • Endoglin-Targeted Cancer Therapy. Seon, Ben K.; Haba, Akinao; Matsuno, Fumihiko; Takahashi, Norihiko; Tsujie, Masanori; She, Xinwei; Harada, Naoko; Uneda, Shima; Tsujie, Tomoko; Toi, Hirofumi; Tsai, Hilda; Haruta, Yuro // Current Drug Delivery;Jan2011, Vol. 8 Issue 1, p135 

    No abstract available.

  • Overexpression of Her-2/neu in Epithelial Ovarian Carcinoma Induces Vascular Endothelial Growth Factor C by Activating NF-κB: Implications for Malignant Ascites Formation and Tumor Lymphangiogenesis. Chang-Yao Hsieh; Chi-An Chen; Chia-Hung Chou; Kuo-Pao Lai; Yung-Ming Jeng; Min-Liang Kuo; Lin-Hung Wei // Journal of Biomedical Science;Mar/Apr2004, Vol. 11 Issue 2, p249 

    Vascular endothelial growth factor C (VEGF-C) is an important growth factor that governs lymphatic spread and the development of intraperitoneal tumors associated with epithelial ovarian cancer; however, its regulation is not yet understood. Overexpression of Her-2/neu is related to poor...

  • VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Gavalas, N G; Tsiatas, M; Tsitsilonis, O; Politi, E; Ioannou, K; Ziogas, A C; Rodolakis, A; Vlahos, G; Thomakos, N; Haidopoulos, D; Terpos, E; Antsaklis, A; Dimopoulos, M A; Bamias, A // British Journal of Cancer;11/20/2012, Vol. 107 Issue 11, p1869 

    Background:Vascular endothelial growth factor action in tumour angiogenesis is well characterised; nevertheless, it functions as a key element in the promotion of the immune system's evasion by tumours. We sought to investigate the possible direct effect of VEGF on T-cell activation and through...

  • Kaempferol enhances cisplantin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Luo, Haitao; Daddysman, Matthew K.; Rankin, Gary O.; Bing-Hua Jiang; Chen, Yi C. // Cancer Cell International;2010, Vol. 10, p16 

    Background: Ovarian cancer is one of the most significant malignancies in the western world. Studies showed that Ovarian cancers tend to grow resistance to cisplatin treatment. Therefore, new approaches are needed in ovarian cancer treatment. Kaempferol is a dietary flavonoid that is widely...

  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Gururangan, S.; Sampson, J. H.; Sathornsumetee, S.; McLendon, R. E.; Herndon, J. E.; Marcello, J. E.; Norfleet, J.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S.; Herndon, J E 2nd // British Journal of Cancer;12/15/2009, Vol. 101 Issue 12, p1986 

    Background: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial.Methods: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10 mg kg(-1)...

  • Managing patients with metastatic colorectal cancer on bevacizumab. Lemmens, Liesbeth; Claes, Viviane; Uzzell, Maggie // British Journal of Nursing;8/14/2008, Vol. 17 Issue 15, p944 

    Bevacizumab (Avastin®) is a humanized monoclonal antibody that inhibits the activity of vascular endothelial growth factor (VEGF), a key molecule controlling tumour blood vessel formation (angiogenesis). By inhibiting VEGF and thus tumour angiogenesis, bevacizumab inhibits tumour growth and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics